Table 2 Logistic regression analysis for the detection of csPCa in the development cohort

 tPSA

1.04 (1.02–1.05)

 < 0.001

1.00 (0.98–1.03)

0.806

 fPSA

1.10 (1.04–1.17)

0.001

0.94 (0.85–1.05)

0.263

 Age

1.02 (0.99–1.05)

0.132

1.03 (0.99–1.07)

0.119

 Prostate volume

0.99 (0.99–1.00)

0.220

 PSAd

9.69 (4.50–20.86)

 < 0.001

13.22 (4.42–39.51)

 < 0.001

 DRE findings

2.30 (1.37–3.88)

0.002

3.60 (1.58–8.24)

0.002

 Family history

1.43 (0.85–2.40)

0.176

0.68 (0.30–1.55)

0.360

bpMRI PI-RADS v2.1-based model

 PI-RADS v2.1 score

3.66 (2.64–5.09)

 < 0.001

2.96 (2.10–4.18)

 < 0.001

 tPSA

1.04 (1.02–1.05)

 < 0.001

1.01 (0.98–1.04)

0.647

 fPSA

1.10 (1.04–1.17)

0.001

0.93 (0.83–1.04)

0.213

 Age

1.02 (0.99–1.05)

0.132

1.02 (0.98–1.07)

0.259

 Prostate volume

0.99 (0.99–1.00)

0.220

 PSAd

9.69 (4.50–20.86)

 < 0.001

4.34 (1.38–13.69)

0.012

 DRE outcome

2.30 (1.37–3.88)

0.002

2.73 (1.07–6.97)

0.036

 Family history

1.43 (0.85–2.40)

0.176

0.84 (0.32–2.19)

0.728